The President of Colombia, Ivan Duque, said on 25 February 2021 that Colombia will extend its health state of emergency to curb the spread of COVID-19 by three months, Reuters news agency reported on Friday.
Colombia's health state of emergency was due to end on 28 February 2021, but will now continue until at least 31 May 2021, Duque said, adding, "The large majority of countries are upholding states of emergency and we will do the same."
Large public events, including concerts, will continue to be suspended, although a return to schools will go ahead, with students alternating between virtual and physical attendance.
Also, Colombia is in talks to buy additional doses of COVID-19 vaccines produced by China's Sinovac Biotech.
Duque added in his nightly television broadcast: "We have also progressed with Sinovac for the additional acquisition of vaccines in our country, which could be around 10 million more doses."
Colombia has already secured five million extra Sinovac doses and is in talks to secure up to an additional five million, Duque was quoted as saying.
Reportedly, Colombia had earlier announced agreements with a several pharmaceutical companies, including Sinovac, as well as the World Health Organisation-backed COVAX initiative, to secure 61.5 million COVID-19 vaccine doses, enough to inoculate about 32.5 million people.
According to the health ministry of Colombia, the country has so far reported over 2.24 million COVID-19 infections, as well as 59,396 deaths.
So far, Colombia has administered 66,000 vaccine doses to health workers and those aged over 80, as per its national vaccination plan.
Merck launches Phase 3 trial for dengue vaccine candidate V181
BioNet and Bio Farma sign MoU on TdaP vaccine
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval
GSK grants USD2m to boost adult vaccination efforts
Valneva and LimmaTech begin Phase 2 infant trial for Shigella vaccine candidate S4V2
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100